News

GSK, CureVac to receive $740M

CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.
GSK secures $500m+ payout in BioNTech, CureVac settlement
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US
WSJ: GSK to Receive $370M in CureVac-BioNTech Vaccine Dispute
Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street
BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition.
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
BioNTech Settles Patent Disputes with CureVac and GSK
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over mRNA vaccine patents. Read more here.
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
CureVac Resolves Patent Litigation with Pfizer/BioNTech
CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of the settlement,
Pfizer, BioNTech Reach Covid Jab Settlement With GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday.

GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
The Washington Post4y

CureVac, the latest experimental coronavirus vaccine, proves just 48 ...

CureVac, the latest experimental coronavirus vaccine, proves just 48 percent effective overall, a disappointing result Company emphasizes that in people 60 and younger, vaccine was 77 percent ...
Pharmabiz1d

BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK

BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...
Medical Marketing & Media1d

Five things for pharma marketers to know: Monday, August 11, 2025

Lack of mRNA funding could pose a national security risk; CureVac, GSK settle mRNA suit against Pfizer, BioNTech; Gilead confident in HIV prevention drug prospects.
The Washington Post4y

CureVac coronavirus vaccine proved just 47 percent effective amid ...

CureVac, latest experimental coronavirus vaccine, proved just 47 percent effective amid spread of variants, preliminary analysis shows The vaccine is the third to use messenger RNA, the technology ...
Pharmaceutical Commerce1d

Pharma Pulse: FDA Launches Pre-Check Program, GSK Secures mRNA Settlement, and Pharma Leaders Eye US Investment Boost

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...